Literature DB >> 34257699

A Real-Time Clinical Decision Support System, for Mild Cognitive Impairment Detection, Based on a Hybrid Neural Architecture.

Carmen Paz Suárez-Araujo1, Patricio García Báez2, Ylermi Cabrera-León1, Ales Prochazka3,4, Norberto Rodríguez Espinosa5, Carlos Fernández Viadero6, For The Alzheimer's Disease Neuroimaging Initiative7.   

Abstract

Clinical procedure for mild cognitive impairment (MCI) is mainly based on clinical records and short cognitive tests. However, low suspicion and difficulties in understanding test cut-offs make diagnostic accuracy being low, particularly in primary care. Artificial neural networks (ANNs) are suitable to design computed aided diagnostic systems because of their features of generating relationships between variables and their learning capability. The main aim pursued in that work is to explore the ability of a hybrid ANN-based system in order to provide a tool to assist in the clinical decision-making that facilitates a reliable MCI estimate. The model is designed to work with variables usually available in primary care, including Minimental Status Examination (MMSE), Functional Assessment Questionnaire (FAQ), Geriatric Depression Scale (GDS), age, and years of education. It will be useful in any clinical setting. Other important goal of our study is to compare the diagnostic rendering of ANN-based system and clinical physicians. A sample of 128 MCI subjects and 203 controls was selected from the Alzheimer's Disease Neuroimaging Initiative (ADNI). The ANN-based system found the optimal variable combination, being AUC, sensitivity, specificity, and clinical utility index (CUI) calculated. The ANN results were compared with those from medical experts which include two family physicians, a neurologist, and a geriatrician. The optimal ANN model reached an AUC of 95.2%, with a sensitivity of 90.0% and a specificity of 84.78% and was based on MMSE, FAQ, and age inputs. As a whole, physician performance achieved a sensitivity of 46.66% and a specificity of 91.3%. CUIs were also better for the ANN model. The proposed ANN system reaches excellent diagnostic accuracy although it is based only on common clinical tests. These results suggest that the system is especially suitable for primary care implementation, aiding physicians work with cognitive impairment suspicions.
Copyright © 2021 Carmen Paz Suárez-Araujo et al.

Entities:  

Year:  2021        PMID: 34257699      PMCID: PMC8257364          DOI: 10.1155/2021/5545297

Source DB:  PubMed          Journal:  Comput Math Methods Med        ISSN: 1748-670X            Impact factor:   2.238


  22 in total

1.  Mild cognitive impairment: clinical characterization and outcome.

Authors:  R C Petersen; G E Smith; S C Waring; R J Ivnik; E G Tangalos; E Kokmen
Journal:  Arch Neurol       Date:  1999-03

2.  Counterpropagation networks.

Authors:  R Hecht-Nielsen
Journal:  Appl Opt       Date:  1987-12-01       Impact factor: 1.980

3.  Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers.

Authors:  Clifford R Jack; David S Knopman; William J Jagust; Ronald C Petersen; Michael W Weiner; Paul S Aisen; Leslie M Shaw; Prashanthi Vemuri; Heather J Wiste; Stephen D Weigand; Timothy G Lesnick; Vernon S Pankratz; Michael C Donohue; John Q Trojanowski
Journal:  Lancet Neurol       Date:  2013-02       Impact factor: 44.182

4.  Mild cognitive impairment and dementia in primary care: the value of medical history.

Authors:  Javier Olazarán; Pedro Torrero; Isabel Cruz; Esperanza Aparicio; Ana Sanz; Nieves Mula; Garbiñe Marzana; Dionisio Cabezón; Concepción Begué
Journal:  Fam Pract       Date:  2011-03-14       Impact factor: 2.267

5.  Rate of progression of mild cognitive impairment to dementia--meta-analysis of 41 robust inception cohort studies.

Authors:  A J Mitchell; M Shiri-Feshki
Journal:  Acta Psychiatr Scand       Date:  2008-02-18       Impact factor: 6.392

6.  Longitudinal study of the transition from healthy aging to Alzheimer disease.

Authors:  David K Johnson; Martha Storandt; John C Morris; James E Galvin
Journal:  Arch Neurol       Date:  2009-10

7.  Spatially augmented LPboosting for AD classification with evaluations on the ADNI dataset.

Authors:  Chris Hinrichs; Vikas Singh; Lopamudra Mukherjee; Guofan Xu; Moo K Chung; Sterling C Johnson
Journal:  Neuroimage       Date:  2009-05-27       Impact factor: 6.556

8.  Comparison of brief cognitive tests and CSF biomarkers in predicting Alzheimer's disease in mild cognitive impairment: six-year follow-up study.

Authors:  Sebastian Palmqvist; Joakim Hertze; Lennart Minthon; Carina Wattmo; Henrik Zetterberg; Kaj Blennow; Elisabet Londos; Oskar Hansson
Journal:  PLoS One       Date:  2012-06-22       Impact factor: 3.240

9.  Mapping longitudinal scientific progress, collaboration and impact of the Alzheimer's disease neuroimaging initiative.

Authors:  Xiaohui Yao; Jingwen Yan; Michael Ginda; Katy Börner; Andrew J Saykin; Li Shen
Journal:  PLoS One       Date:  2017-11-02       Impact factor: 3.240

10.  Discrimination between Alzheimer's disease and mild cognitive impairment using SOM and PSO-SVM.

Authors:  Shih-Ting Yang; Jiann-Der Lee; Tzyh-Chyang Chang; Chung-Hsien Huang; Jiun-Jie Wang; Wen-Chuin Hsu; Hsiao-Lung Chan; Yau-Yau Wai; Kuan-Yi Li
Journal:  Comput Math Methods Med       Date:  2013-05-07       Impact factor: 2.238

View more
  2 in total

Review 1.  Biomarkers for Alzheimer's Disease in the Current State: A Narrative Review.

Authors:  Serafettin Gunes; Yumi Aizawa; Takuma Sugashi; Masahiro Sugimoto; Pedro Pereira Rodrigues
Journal:  Int J Mol Sci       Date:  2022-04-29       Impact factor: 6.208

2.  A Study on the Correlation Between Age-Related Macular Degeneration and Alzheimer's Disease Based on the Application of Artificial Neural Network.

Authors:  Meng Zhang; Xuewu Gong; Wenhui Ma; Libo Wen; Yuejing Wang; Hongbo Yao
Journal:  Front Public Health       Date:  2022-06-30
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.